Skip to main content
Clinical Trials/EUCTR2010-020698-17-BE
EUCTR2010-020698-17-BE
Active, not recruiting
Not Applicable

Study of the vascular wall with functional imaging in OSA patients.

Antwerp University Hospital : Department Respiratory Medicine0 sitesOctober 7, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obstructive sleep apnea (OSA) is a prevalent disorder and characterised by sleepiness during the daytime, fatigue and impairments of concentration. OSA can also lead to cardiovascular pathology due to an increase of sympathetic activity and possibly also by complex inflammatory processes and oxidative stress at the vascular wall due to intermittent hypoxemia. It is particularly important to modulate and describe the structure of the vascular wall in this population.
Sponsor
Antwerp University Hospital : Department Respiratory Medicine
Status
Active, not recruiting
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2010
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Antwerp University Hospital : Department Respiratory Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. male or female \>25 years
  • 2\. OSA patients with AHI\>20
  • 3\. Eligible for CPAP therapy according to the Belgian OSA convention
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\. patients who cannot delay CPAP therapy
  • 2\. excessive disturbing sleepiness in opinion of the doctor who advises immediate treatment
  • 3\. pregnancy/lactation or becoming pregnant during the study period
  • 4\. common cold the last 2W before the start of the study
  • 5\. significant GI, liver, cardiovascular, neurological, renal or hematologic disease, uncontrolled with the current treatment
  • 6\. use of ICS, nasal and oral corticosteroids, NAC, statins, antibiotic use 8 weeks before the start of the study
  • 7\. patients with dislipidemia (totaal CH \> 240 mg/dl, LDL \> 160, HDL\<35, TG\>200\)
  • 8\. use of vitamines
  • 9\. coronary artery disease
  • 10\. diabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials